Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group

被引：0
|
作者：
Dennis A. Eichenauer
Annette Plütschow
Michael Fuchs
Sylvia Hartmann
Martin-Leo Hansmann
Boris Böll
Bastian von Tresckow
Peter Borchmann
Andreas Engert
机构：
[1] Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf,First Department of Internal Medicine
[2] University of Cologne,German Hodgkin Study Group (GHSG)
[3] University Hospital Cologne,Senckenberg Institute of Pathology
[4] University Hospital Frankfurt,undefined
来源：
Leukemia | 2020年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：953 / 956
页数：3
相关论文
共 50 条
  • [21] The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)
    Hartmann, Sylvia
    Eichenauer, Dennis A.
    Pluetschow, Annette
    Mottok, Anja
    Bob, Roshanak
    Koch, Karoline
    Bernd, Heinz-Wolfram
    Cogliatti, Sergio
    Hummel, Michael
    Feller, Alfred C.
    Ott, German
    Moeller, Peter
    Rosenwald, Andreas
    Stein, Harald
    Hansmann, Martin-Leo
    Engert, Andreas
    Klapper, Wolfram
    BLOOD, 2013, 122 (26) : 4246 - 4252
  • [22] Lymphocyte-predominant and classical Hodgkin's lymphoma:: A comprehensive analysis from the German Hodgkin study group
    Nogova, Lucia
    Reineke, Thorsten
    Brillant, Corinne
    Sieniawski, Michal
    Ruediger, Thomas
    Josting, Andreas
    Bredenfeld, Henning
    Skripnitchenko, Roman
    Mueller, Rolf-Peter
    Mueller-Hermelink, Hans-Konrad
    Diehl, Volker
    Engert, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) : 434 - 439
  • [23] Rituximab in relapsed lymphocyte predominant Hodgkin's disease (LPHD). Long-term results of a phase-II study from the German Hodgkin Lymphoma Study Group (GHSG).
    Schulz, H
    Trelle, S
    Reiser, M
    Sieber, M
    Diehl, V
    Engert, A
    BLOOD, 2005, 106 (11) : 433A - 433A
  • [24] Treatment of Early-Stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Subgroup Analysis of the Randomized German Hodgkin Study Group HD16 Study
    Eichenauer, Dennis A.
    Buehnen, Ina
    Fuchs, Michael
    Kaul, Helen
    Kobe, Carsten
    Hartmann, Sylvia
    Baues, Christian
    Von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    BLOOD, 2021, 138
  • [25] Long-Term Outcomes in Patients with Early Stage Nodular Lymphocyte-Predominant Hodgkin's Lymphoma Treated with Radiotherapy
    Solanki, Abhishek A.
    LeMieux, Melissa Horoschak
    Chiu, Brian C. -H.
    Mahmood, Usama
    Hasan, Yasmin
    Koshy, Matthew
    PLOS ONE, 2013, 8 (09):
  • [26] PET-2-guided escalated BEACOPP for patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group
    Eichenauer, D. A.
    Kreissl, S.
    Buehnen, I.
    Goergen, H.
    Hartmann, S.
    Fuchs, M.
    von Tresckow, B.
    Engert, A.
    Borchmann, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 87 - 88
  • [27] Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma - a matched pair analysis from the German Hodgkin Study Group (GHSG)
    Hartmann, Sylvia
    Eichenauer, Dennis A.
    Pluetschow, Annette
    Mottok, Anja
    Bob, Roshanak
    Koch, Karoline
    Bernd, Heinz-Wolfram
    Cogliatti, Sergio
    Hummel, Michael
    Feller, Alfred C.
    Ott, German
    Moeller, Peter
    Rosenwald, Andreas
    Stein, Harald
    Hansmann, Martin-Leo
    Engert, Andreas
    Klapper, Wolfram
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (02) : 238 - 242
  • [28] LONG-TERM OUTCOME OF PATIENTS WITH NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA TREATED WITHIN THE RANDOMIZED HD7-HD15 TRIALS: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP
    Eichenauer, D. A.
    Pluetschow, A.
    Fuchs, M.
    von Tresckow, B.
    Diehl, V.
    Borchmann, P.
    Engert, A.
    HAEMATOLOGICA, 2017, 102 : 82 - 82
  • [29] Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group
    Eichenauer, Dennis A.
    Buehnen, Ina
    Pluetschow, Annette
    Kobe, Carsten
    Dietlein, Markus
    Wendtner, Clemens-Martin
    Thorspecken, Sven
    Topp, Max S.
    Mauser, Mareike
    von Tresckow, Bastian
    Fuchs, Michael
    Borchmann, Peter
    Engert, Andreas
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 801 - 804
  • [30] Treatment options for lymphocyte-predominant Hodgkin's disease (LPHD) in clinical stage IA: Review of the German Hodgkin Study Group (GHSG).
    Engert, A
    Nogova, L
    Josting, A
    Brillant, C
    Reineke, T
    Eich, H
    Mueller, RP
    Diehl, V
    BLOOD, 2002, 100 (11) : 570A - 571A
12345